Trial reportAmerican journal of respiratory and critical care medicine2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One
Abstract readClinical Trial, Phase IIIMulticenter Study
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.Annals of the American Thoracic Society · 2026Trial
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Elexacaftor-tezacaftor-ivacaftor for individuals with residual CFTR activity: an open-label, nonrandomized clinical trial.Annals of the American Thoracic Society · 2026Article
- Bridging the Gap in Eastern European Cystic Fibrosis Care: How Newborn Screening and Advanced CFTR Modulation Shape the Clinical Landscape in Western Romania.Children (Basel, Switzerland) · 2026Article
- From bilirubin to breakthroughs: Contemporary outcomes in pediatric liver transplantation for cystic fibrosis.Journal of pediatric gastroenterology and nutrition · 2026Article
- Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19.Pulmonary therapy · 2026Article
- Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis.Advances in therapy · 2026Article
- Article
- Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study.Journal of clinical medicine · 2026Article
- Xenon-129 magnetic resonance imaging detects ongoing ventilation improvements in people with cystic fibrosis receiving highly effective modulator therapy.Annals of the American Thoracic Society · 2026Article
- The clinical, psychosocial, and economic burden of cystic fibrosis lung disease in the era of CFTR modulator therapy.Annals of the American Thoracic Society · 2026Review
- The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Challenges and opportunities for drug development in rare pulmonary diseases like cystic fibrosis: an industry perspective.Current opinion in pulmonary medicine · 2025Review
- Aging Gracefully: Does Elexacaftor/Tezacaftor/Ivacaftor Safety and Efficacy Stand the Test of Time?American journal of respiratory and critical care medicine · 2025Article
- Article
- An alternative view of changes in lung function among people with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025Article
- Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence.Journal of clinical medicine · 2025Review
Corrections and comments
- Commented on by
Authors and funding
22 authors.
Cori L DainesUniversity of Arizona, Banner University Medical Center, Tucson, Arizona.
Deepika PolineniWashington University in St. Louis, St. Louis, Missouri.ORCID 0000-0001-8551-3734
Elizabeth TullisSt. Michael's Hospital, Toronto, Ontario, Canada.
Stefano CostaUniveristy of Messina, Messina, Italy.
Rachel W LinnemannEmory University, Children's Healthcare of Atlanta, Atlanta, Georgia.ORCID 0000-0002-6839-0936
Marcus A MallDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-4057-2199
Edward F McKoneSt. Vincent's University Hospital, Dublin, Ireland.ORCID 0000-0002-5455-8208
Bradley S QuonUniversity of British Columbia and St. Paul's Hospital, Vancouver, British Columbia, Canada.
Felix C RingshausenHannover Medical School and German Center for Lung Research, Hannover, Germany.
Hiran SelvaduraiThe Children's Hospital at Westmead, Westmead, New South Wales, Australia.
Jennifer L Taylor-CousarNational Jewish Health, Denver, Colorado.
Nicholas J WithersRoyal Devon University Hospitals Trust, Exeter, United Kingdom.
Gregory S SawickiBoston Children's Hospital, Boston, Massachusetts.
Timothy LeeLeeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Neil AhluwaliaVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Jessica Morlando GeigerVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Mark JenningsVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Yaoyuan Vincent TanVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
David WaltzVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Bonnie RamseySeattle Children's Hospital, Seattle, Washington; and.
Matthias GrieseLudwig Maximilian University and German Center for Lung Research, Munich, Germany.ORCID 0000-0003-0113-912X
VX17-445-105 Study Group
Funding
Vertex Pharmaceuticals
Abstract
PubMed holds no abstract for this paper.
Indexed as
AminophenolsBenzodioxolesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorIndolesPyrazolesPyridinesAdolescentAdultAllelesChildChloride Channel AgonistsDrug CombinationsFemaleGenotypeHumansAminophenolsBenzodioxolesChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorDrug Combinationselexacaftorelexacaftor, ivacaftor, tezacaftor drug combinationIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolinesQuinolonesQuinoxalinescystic fibrosiselexacaftorivacaftorlong-termtezacaftor
Identifiers
PMID
40209082What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.